William Blair restated their buy rating on shares of Loxo Oncology (NASDAQ:LOXO) in a research note issued to investors on Monday morning.
Several other equities analysts have also recently issued reports on the company. ValuEngine upgraded Loxo Oncology from a hold rating to a buy rating in a research report on Monday, April 2nd. Morgan Stanley cut Loxo Oncology from an overweight rating to an equal weight rating and set a $103.00 price target on the stock. in a research report on Wednesday, March 21st. They noted that the move was a valuation call. Zacks Investment Research upgraded Loxo Oncology from a hold rating to a buy rating and set a $148.00 price target on the stock in a research report on Friday, March 9th. Citigroup restated a buy rating and issued a $151.00 price target (up previously from $108.00) on shares of Loxo Oncology in a research report on Monday, March 5th. Finally, Stifel Nicolaus restated a buy rating and issued a $135.00 price target on shares of Loxo Oncology in a research report on Friday, March 2nd. Twelve equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Loxo Oncology has an average rating of Buy and an average price target of $131.89.
LOXO opened at $133.45 on Monday. Loxo Oncology has a one year low of $42.11 and a one year high of $136.52.
Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.22) by $0.53. The firm had revenue of $21.30 million for the quarter. sell-side analysts anticipate that Loxo Oncology will post 0.3 earnings per share for the current year.
In other Loxo Oncology news, insider Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $88.21, for a total value of $271,863.22. Following the sale, the insider now owns 1,541 shares of the company’s stock, valued at approximately $135,931.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jennifer Burstein sold 1,700 shares of Loxo Oncology stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $93.24, for a total value of $158,508.00. Following the completion of the sale, the vice president now directly owns 1,700 shares in the company, valued at approximately $158,508. The disclosure for this sale can be found here. Insiders sold a total of 72,646 shares of company stock worth $7,600,358 in the last ninety days. 27.80% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. QS Investors LLC purchased a new stake in Loxo Oncology in the 4th quarter valued at approximately $118,000. Xact Kapitalforvaltning AB purchased a new stake in Loxo Oncology in the 4th quarter valued at approximately $208,000. Cambridge Investment Research Advisors Inc. boosted its holdings in Loxo Oncology by 26.8% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 617 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in Loxo Oncology by 195.8% in the 3rd quarter. Great West Life Assurance Co. Can now owns 2,958 shares of the biopharmaceutical company’s stock valued at $275,000 after purchasing an additional 1,958 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Loxo Oncology in the 4th quarter valued at approximately $323,000.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/17/loxo-oncology-loxo-earns-buy-rating-from-william-blair.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.